EPIRUS Biopharmaceuticals Seeks British Columbia Securities Commission Order That It Is No Longer A Reporting Issuer
BOSTON--(BUSINESS WIRE)--EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS), a Boston-based pharmaceutical company focused on the global development of biosimilar monoclonal antibodies, has applied to the British Columbia Securities Commission (the “BCSC”) to cease to be a reporting issuer in Canada.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.